ORIGINAL CONTRIBUTION. Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease

Size: px
Start display at page:

Download "ORIGINAL CONTRIBUTION. Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease"

Transcription

1 ORIGINAL CONTRIBUTION Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease Vahram Haroutunian, PhD; Dushyant P. Purohit, MD; Daniel P. Perl, MD; Deborah Marin, MD; Khalid Khan, MD; Melinda Lantz, MD; Kenneth L. Davis, MD; Richard C. Mohs, PhD Background: The relationship between neuropathological lesions and mild, preclinical, cognitive impairments of Alzheimer disease is poorly understood. Identification of the lesions that are most closely associated with the earliest symptoms of Alzheimer disease is crucial to the understanding of the disease process and the development of treatment strategies to affect its progression. Design and Main Outcome Measures: We examined the extent of neurofibrillary tangles (NFTs) in 4 neocortical regions, the hippocampus, the entorhinal cortex, and the amygdala in 65 elderly subjects with no dementia, questionable dementia, mild dementia, or moderate dementia as assessed using the Clinical Dementia Rating Scale(CDR). Setting and Patients: Postmortem study of nursing home residents. Results: Neurofibrillary tangles were present in the entorhinal cortex and the hippocampus of all subjects, including those without cognitive deficits. Neocortical NFTs were mostly absent in the nondemented (CDR score, 0.0) subjects. The density of NFTs in the questionably demented (CDR score, 0.5) subjects was not significantly increased (P.20) relative to the nondemented group in any of the brain regions studied. Significant increases (P.04) in NFT density become apparent first in the amygdala and the temporal cortex in subjects rated to be mildly impaired (CDR score, 1.0). By the time that cognitive impairments were judged to be moderately severe (CDR score, 2.0), all regions of the brain examined, except for the occipital cortex, were significantly (P.05) involved. Conclusions: Some NFTs are present in the entorhinal cortex and hippocampus of most elderly individuals irrespective of their cognitive status, but the density of NFTs increases as a function of dementia severity. Arch Neurol. 1999;56: From the Departments of Psychiatry (Drs Haroutunian, Marin, Khan, Davis, and Mohs) and Pathology (Drs Purohit and Perl), The Mount Sinai School of Medicine, New York, NY; Psychiatry Service, Bronx Veteran Affairs Medical Center, Bronx, NY (Drs Haroutunian, Purohit, Perl, Marin, Khan, Davis, and Mohs) ; and Jewish Home and Hospital, New York (Dr Lantz). ACRITICAL question in understanding the classic neuropathological features of Alzheimer disease (AD) (neuritic plaques [NPs] and neurofibrillary tangles [NFTs]) 1-3 is whether they precede, follow, or occur in synchrony with the earliest and mildest signs of cognitive deterioration. Although the commonly used formal neuropathological diagnostic criteria for AD rely almost exclusively on the density of neocortical NPs, 4,5 several studies 6-9 have argued that the development of NFTs, especially in the entorhinal cortex, represents the earliest neuropathological change in AD. In fact, a recent consensus recommendation for the neuropathological diagnosis of AD 10 has advised that in addition to the evaluation of NPs, the density and distribution of NFTs be considered in establishing a diagnosis of AD. Frequently, diagnostic approaches to AD reflect the progression of the identified neuropathological lesions 6,11,12 but overlook or minimize the role of the cognitive symptoms of the disease, especially when these deficits are mild or moderate. 13,14 While the importance of NFTs to AD and its neuropathological diagnosis cannot be minimized, the relationship of NFTs to the earliest stages of AD and to the onset of dementia and cognitive dysfunction remains elusive. Some investigators 6,13,15-17 have argued that the presence of NFTs is evidence of a pathological process and that, when they occur in the absence of cognitive deficits, they represent the preclinical or incipient manifestations of AD. Other investigators 15,18 have suggested that since NFTs can be identified in the brains of nondemented elderly subjects and because their density can correlate with the age of the subjects, they should be treated as a consequence of the aging process. Furthermore, while NFTs may be necessary for the expression of dementia, by themselves, they are not sufficient for dementia. 15,18 Thus, although the 713

2 SUBJECTS AND METHODS SUBJECTS Sixty-five subjects constituted the principal cohort of this postmortem study. The subjects were selected from a group of 278 who had been residents of the Jewish Home and Hospital in Manhattan and Bronx, NY, an academic affiliate of the Mount Sinai School of Medicine, New York, NY. This cohort was part of a larger clinical and epidemiological study of early AD in which all consenting residents and new admissions to the Jewish Home and Hospital were given mental status screening tests, with more detailed clinical evaluations performed on patients without dementia or on patients with mild cognitive impairment. All assessment procedures were approved by the Jewish Home and Hospital and the Mount Sinai School of Medicine institutional review boards, and consent for autopsy was obtained from each subject s legal next of kin. Because the aim of this study was to identify the relationship between NFTs and early and mild dementia, only those subjects with CDR scores of 0.0 to 2.0 (see Final Case Selection subsection) were selected for inclusion. Many of the subjects included in this series died without undergoing neuropsychological testing because the testing began after the subjects had entered the Jewish Home and Hospital. However, detailed clinical records are available for all residents, and research staff conduct detailed interviews with staff and family caregivers to obtain information about the antemortem functional and cognitive status of the patients. The subject selection criteria were based on neuropathological and cognitive measures. Initially, all subjects with non ADrelated neuropathological lesions or AD-related neuropathological lesions complicated by other neuropathological lesions of sufficient magnitude to contribute to cognitive dysfunction were excluded from consideration. These neuropathological lesions included, but were not limited to, Pick disease, Lewy body inclusions, Parkinson disease, stroke, multi-infarct dementia, and severe cerebrovascular disease. Subjects with mild cerebrovascular disease judged to be insufficient in severity to affect cognitive function 2,23 were not excluded. A multistep approach was applied to the assignment of CDR scores based on cognitive and functional status during the last 6 months of life. Initially, a CDR score was obtained by careful review (K.K. and V.H.) of all information within each patient s medical chart (admitting diagnoses, nurse s notes, social work records, results of psychiatric and neurologic consultations, medication histories, results of mental status testing, and all other medical records and laboratory studies). These same records were then examined by a second reviewer to obtain a second independent CDR score. Subsequently, the second reviewer or another member of the cognitive assessment team conducted telephone interviews with at least 1 family member or caregiver for each subject and assigned a third CDR score. The interrater reliability for 40 subjects undergoing consecutive assessment was high (interclass correlation, 0.88). All 3 CDR scores and all pertinent medical chart information were then presented to a senior clinician (D.M.), and a consensus CDR score was derived. The correlation between the initial postmortem medical chart review CDR scores and the final consensus CDR scores was r = 0.96 (P.001). The reliability of the postmortem medical chart review procedure for CDR scoring was established in a pilot study. Clinical Dementia Rating Scale scores were determined by direct observation and patient interview, and by medical chart review alone for 35 subjects. An interclass correlation coefficient of 0.86 was obtained for the 2 independent assessments of CDR. A subset of the subjects (n = 22) had undergone neuropsychological assessment and had been assessed using the Mini-Mental State Examination 30 and the Alzheimer s Disease Assessment Scale. 31 These assessments were also considered in deriving the final consensus CDR score. The correlation between the consensus CDR score assigned and the Mini-Mental State Examination score was 0.48 (P =.03). If only those subjects who had received a Mini-Mental State Examination score within 1 year of death were considered (n = 14), then the correlation between the consensus CDR score and the last Mini- Mental State Examination score rose to 0.73 (P =.003). results of most studies show that some NFTs are present in the brains of apparently nondemented elderly subjects, 6,18-23 the significance of these lesions to AD, aging, and dementia remains uncertain. 24 Some of the uncertainty regarding the relative importance of NFTs to AD and its dementia stems from a lack of studies that have systematically assessed the degree of NFT lesions in a large and well-characterized cohort of subjects with graded dementia in the mild to moderate range (with the exception of the study by Berg et al 25 ). From the perspective of the current investigation, the critical question is the degree to which NFTs are related to the dementia of AD and whether NFTs in one brain region are more closely associated with the earliest signs of dementia than in other regions. We determined the extent and regional distribution of NFTs in a group of patients who died with cognitive and functional status characteristic of early or mild AD (a similar analysis has been performed recently 26 examining the relationship between NPs and cognitive status in the subjects studied in this article). We grouped the study cohort based on Clinical Dementia Rating Scale (CDR) scores, which were assigned without knowledge of the neuropathological lesions and without regard to neuropathological diagnoses. Neuropathological considerations were applied to exclude only those specimens that had sufficient non AD-related neuropathological lesions with potential to cause dementia. This grouping strategy made it possible to determine the extent and distribution of NFTs in subjects at various early stages of cognitive impairment. RESULTS The median densities of NFTs in the 4 neocortical regions and in the hippocampus, entorhinal cortex, and amygdala are shown in Figure 1. To depict the occurrence of NFTs in the different brain regions more clearly, the results are plotted as the proportion of subjects receiving NFT ratings of none vs NFT ratings of sparse or 714

3 NEUROPATHOLOGICAL ASSESSMENT Autopsy, tissue dissection, and neuropathological procedures were identical to those described earlier. 26 All neuropathological studies were performed on the right hemisphere by 2 of us (D.P.P. and D.P.P.). The data on the density and distribution of neuropathological lesions were obtained without knowledge of the cognitive status of the subjects. Every subject underwent evaluation for the extent of neuropathological lesions using the Consortium to Establish a Registry for Alzheimer sdisease(cerad)neuropathologicalbattery. 5 Although the full CERAD neuropathological battery (supplemented with additional regions of assessment) was performed for each subject, only data from examination of the NFTs in the hippocampus(ca1), entorhinal cortex, amygdala, middle frontal gyrus, superior and middle temporal gyrus, inferior parietallobule, andoccipitalcalcarinecortex(area17) arepresented. As part of the neuropathological assessment and diagnosis procedures, sections (5-8 µm thick) from paraffinembeddedblockswerestainedusinghematoxylin-eosin, modifiedbielschowsky,modifiedthioflavines,anti -amyloid,and anti-. Any case showing evidence of Lewy body formation (anti-ubiquitin [Daka Corp, Carpinteria, Calif] staining) was excluded from this study. Multiple (5 in general) high-power (200X, 0.5 mm 2 ) fields were examined on each slide, and the density of NFTs was rated on a 4-point scale of absent, sparse, moderate, or severe according to the scoring criteria established by CERAD. When NFTs were unevenly distributed in a slide, NFTs in the region with the highest density were rated. Assessments of NFTs were based primarily on modified Bielschowsky staining. FINAL CASE SELECTION After the completion of the neuropathological studies and assignment of consensus CDR scores, a final consensus conference was held (V.H., D.P.P., D.P.P., D.M., K.L.D., and R.C.M.) for the selection of subjects for inclusion in the study. Using the criteria for selection previously outlined, the original cohort of potential subjects was reduced to 65 subjects who met all of the inclusion and exclusion criteria described. Four groups of subjects were formed, consisting of subjects with CDR scores of 0.0 (cognitively intact), 0.5 (questionable dementia), 1.0 (mildly impaired), and 2.0 (moderately impaired). A fifth group was formed from a cohort with CDR scores of 4.0 and 5.0 (severely demented) 29 to provide an extreme comparison group (Table 1). Because the focus of the study was on the association between NFTs and cognitive deficits, the study groups were formed based purely on their CDR scores without regard to the extent of NFTs or NPs present. However, the distribution of the subjects for neuropathological diagnoses within each CDR category is presented in Table 2. Groups formed based on CDR scores did not differ significantly on age (F 3,62 = 1.8, P =.15). There were significantly (P =.006) more women (n = 51) than men (n = 14) in the study cohort (Table 1), but the proportion of men and women in the different CDR groups did not differ significantly ( 2 3= 0.8, P =.82). DATA ANALYSES The principal study cohort consisted of the subjects with CDR scores of 0.0, 0.5, 1.0, and 2.0. The 4 CDR categories were used as the independent variable for subsequent analyses. Since the study examined the neuropathological features of early AD or mild dementia, results from the extreme comparison group (CDR scores of 4.0 and 5.0) were not used in any of the statistical tests, but their data are presented in the tables and figures for illustrative purposes. The dependent variables consisted of the CERAD ratings of NFT density in the regions specified. Because the measures were based on ordinal CERAD ratings, they were analyzed by Kruskal-Wallis analyses of variance (ANOVAs) for each region. For individual group comparisons, Mann-Whitney U tests were performed when significant overall differences were revealed by the Kruskal-Wallis tests. Differences in NFT densities across brain regions were analyzed by Friedman ANOVAs for related samples. Wilcoxon matched pairs tests were used for post hoc analysis of differences between brain regions within any given CDR grouping. To determine the correlation between CDR scores and NFT density, Spearman rank order procedures were used. greater as a function of CDR scores in Figure 2 (top and bottom, respectively). Region-by-region Kruskal-Wallis ANOVAs showed significant differences in NFT density as a function of CDR score in each brain region (Hs [3,64] 7.8, P.05), except for the primary visual cortex where NFT density score differences between the different CDR groups were not significantly different (H [3,64] = 3.3, P =.35). Relative to the cognitively unimpaired group (CDR score, 0.0), significant increases in the density of NFTs first emerged in the amygdala and the superior and medial temporal cortex in subjects with CDR ratings of 1.0 or greater (Mann-Whitney U tests, P.04). As the severity of cognitive deficits increased to a rating of moderately impaired (CDR score, 2.0), the density of NFTs increased further in the temporal neocortex and amygdala (P.02). In the hippocampus, entorhinal cortex, middle frontal gyrus, and inferior parietal lobule, the density of NFTs increased significantly (P.05) relative to the nondemented group only in those subjects who were rated as moderately demented (CDR score, 2.0). The proportion of subjects in each CDR category with different NFT density ratings in the temporal cortex is shown in Table 2, bottom. Comparisons of NFT density ratings between brain regions at each CDR stage by Friedman ANOVAs showed significant regional differences in NFT severity at every CDR stage ( 2 54, P.001). The density of NFTs in all CDR groups was significantly greater in the entorhinal cortex relative to all other regions (P.02) except for the hippocampus, where the density of NFTs did not differ significantly from the density of NFTs in the entorhinal cortex of the groups with CDR scores of 0.5, 1.0, and 2.0 (P.06). The densities of NFTs in the occipital cortex were always lower than those in any other region at any given CDR stage (P.001). Neurofibrillary tangles were virtually absent in the neocortices of most subjects who had CDR scores in the 0.0 to 1.0 range (Figures 1 and 2). In the subjects with a CDR score of 2.0, the density of NFTs was significantly higher (P.05) in the middle frontal gyrus and in the superior and middle temporal 715

4 Table 1. Demographic Characteristics of the Sample* CDR Group All Sample size Mean ± SD PMI, h 8.29 ± ± ± ± ± ± 5.07 Age, y Mean ± SD (range) 83.8 ± 9.9 (64-99) 85.8 ± 8.3 (69-94) 82.9 ± 8.2 (74-103) 89.1 ± 5.7 (74-97) 85.4 ± 10.3 (62-103) 86.7 ± 8.9 (62-103) Male Female Sex, No. Male Female *CDR indicates Clinical Dementia Rating Scale; PMI, postmortem interval. CDR group 0.0 indicates cognitively intact; 0.5, questionable dementia; 1.0, mildly impaired; 2.0, moderately impaired; and 4.0 and 5.0, severely demented. Table 2. Neuropathological Diagnoses and Neurofibrillary Tangle Characteristics of Study Subjects* CDR Group Neuropathological Diagnoses Normal Alzheimer disease Definite Probable Possible Total Subjects Receiving Each Neurofibrillary Tangle Density Rating Score in the Superior and Middle Temporal Subject, % None Sparse Moderate Severe *CDR indicates Clinical Dementia Rating Scale. An explanation of the CDR groups is given in the footnote to Table 1. None indicates a Consortium to Establish a Registry for Alzheimer s Disease (CERAD) score of 0; sparse, CERAD score of 1; moderate, CERAD score of 3; and severe, CERAD score of 5. gyri than in the inferior parietal lobule, which had a greater density of NFTs than the occipital cortex (P.03). Comparison of the median NFT density scores of subjects with CDR scores of 4.0 and (Figure 1) suggests that even when cognitive deficits were rated as severe or terminal, NFT densities in the neocortical regions were less profound than in the hippocampus, entorhinal cortex, and amygdala (P.05). The density of NFTs in the frontal, temporal, and parietal neocortical regions and the amygdala (but not in the hippocampus and entorhinal cortex) increased in the severely demented group (CDR scores, 4.0 and 5.0) relative to the moderately impaired group (CDR scores, 2.0) (Mann- Whitney U tests, P.03). The density of NFTs in the different brain regions examined correlated significantly with the level of cognitive impairment. With the exception of the occipital cortex, NFT ratings were significantly and positively correlated with the CDR scores in each of the brain regions (Spearman rank order r range, ; P.001). The Neurofibrillary Tangles (CERAD Rating) Middle Frontal Superior Temporal Inferior Parietal Lobule Occipital CDR Stage correlation of NFT density with CDR scores was highest for the superior and medial temporal cortical region (r = 0.54, P.001). The age of the subjects was also positively correlated with the density of NFTs in all of the regions examined, except for the occipital cortex (Spearman rank order r range, ; P.05). Analysis of partial correlations controlling for age showed that the correlation of CDR scores with NFT density was not accounted for by the age of the subjects. The range of correlations of CDR with NFT density ratings remained significant for all regions (r range, ; P.04), except for the occipital cortex (r = 0.18, P =.16), even after controlling for age. COMMENT Amygdala Entorhinal Hippocampus Figure 1. Density of neurofibrillary tangles in the 4 neocortical regions and in the entorhinal cortex, hippocampus, and amygdala in nondemented (Clinical Dementia Rating Scale [CDR] score, 0.0), questionably demented (CDR score, 0.5), mildly demented (CDR score, 1.0), and moderately demented (CDR score, 2.0) subjects. Data on severely demented subjects (CDR score, 4.0 and 5.0) are provided for comparison. The y-axis represents the median of Consortium to Establish a Registry for Alzheimer s Disease (CERAD) neurofibrillary tangle ratings (0 indicates none; 1, sparse; 3, moderate; and 5, severe). The results of this study show that the density of NFTs in most regions of the cerebral cortex, hippocampus, and amygdala increases significantly as a function of increas- 716

5 ing cognitive impairment in elderly subjects. Unlike our previously observed increase in the density of NPs in the neocortex of subjects with CDR scores of 0.5, 26 the density of NFTs in the questionably demented (CDR score, 0.5) subjects was not significantly increased relative to the nondemented group in any of the brain regions studied. Significant increases in NFT density, relative to nondemented subjects, become apparent first in the amygdala and the temporal cortex in subjects rated to be mildly impaired (CDR score, 1.0). By the time that cognitive impairments were judged to be moderately severe (CDR score, 2.0), all regions of the brain examined, except for the occipital cortex, were significantly involved. These results are in general agreement with the recently published work of Berg et al. 25 Increases in the density of NFTs beyond those present in the cognitively intact group became evident only in the subjects with CDR scores of 1.0, suggesting that NFTs are not associated with the first signs of cognitive impairment. It is possible that increased densities of NFTs in other brain regions may more closely reflect the earliest stages of cognitive dysfunction. Initial exploratory analyses failed to reveal any differences in NFT densities between the group with a CDR score of 0.0 and the group with a CDR score of 2.0 in the nucleus basalis of Meynert, substantia nigra, dorsal raphe nucleus, locus ceruleus, dorsal vagus nucleus, lateral cerebellum, cerebellar vermis, thalamus, hypothalamus, and mamillary bodies. Although it is possible that more quantitative techniques for NFT assessment, such as direct counting of NFT-bearing neurons or measures of neurofibrillary threads, would have allowed discrimination of the group with a CDR score of 0.5 from the group with a CDR score of 0.0, the results did not suggest a significant trend in this direction. It is unlikely that the failure to observe differences between the group with a CDR score of 0.0 and the group with a CDR score of 0.5 was due to a failure to accurately assign subjects to these CDR groups, since in our earlier study 26 this same grouping of the same subjects showed clear differences in NP density between these 2 groups. Several inferences can be derived from these observations. The fact that NFTs were observed in the hippocampus and entorhinal cortex of most of the nondemented subjects ( 94%) suggests that some NFT pathological features in these regions may be relatively benign, occurring as a consequence of advanced age without causing discernable cognitive impairments. Furthermore, as illustrated in Figures 1 and 2, the density of NFTs in the entorhinal cortex of more than 50% of the subjects in the group with a CDR score of 0.0 was rated as moderate or severe. Other investigators 14,18,20-22,32,33 have made similar observations about the presence of NFTs in the entorhinal cortex of clinically nondemented subjects, but Berg et al 25 had discordant findings. Although the argument that these nondemented subjects with NFTs in the hippocampus and in the entorhinal cortex may represent cases of early AD or incipient AD cannot be denied, 8,32,34 this proposition would imply that most of the nondemented subjects in our study cohort suffered from incipient AD. Given the robust correlation of entorhinal cortex NFT densities with the age of the subjects, a more Proportion of Subjects With NFT Density Ratings of None Proportion of Subjects With NFT Density Ratings of Sparse, Moderate, or Severe Middle Frontal Superior Temporal Inferior Parietal Lobule Occipital Amygdala Entorhinal Hippocampus CDR Stage Figure 2. Proportion of subjects neurofibrillary tangle (NFT) rating scores of none in each of the 7 brain regions examined and in each Clinical Dementia Rating Scale (CDR) category (top). Proportion of subjects NFT rating scores of sparse or greater in each of the 7 brain regions examined and in each CDR category (bottom). parsimonious interpretation is that entorhinal cortex and hippocampal NFTs are associated with advanced age and by themselves are not sufficient for the expression of dementia. 15 The observed differences in the density of NFTs in the hippocampus and entorhinal cortex vs the neocortical regions examined suggest that the distribution of NFTs within the brain varies as a function of the degree of cognitive impairment (Figure 1). The hippocampus and entorhinal cortex are involved in the elderly even in the absence of cognitive deficits, but the degree of their involvement increases with increasing dementia severity. In the neocortex, NFTs are absent in nonimpaired and questionably impaired subjects, but increasing cognitive impairment is associated with the appearance of NFTs with densities that are in the sparse to moderate range. In this respect, the results reported are similar to those presented by Braak and Braak 6 and suggest a regional progression of NFT pathological features from the hippocampus and entorhinal cortex to the neocortex. In general, our observations suggest that the presence of NFTs in the brain is not diagnostic of AD, but that NFTs should be viewed as pathological markers that may be associated with the evolution of dementia. These results raise the question of what other features of AD 717

6 may be more closely associated with the initial onset of dementia. Clearly, neuronal loss, 33 decreases in the density of synapses, 35 deficits in neurotransmitter systems, 36 and the density of NPs and -amyloid burden, 15,26 among other AD-related neuropathological features, are all potential candidates for close correlates of early dementia. In fact, in a study 26 of the density of NPs in the same brain regions and subjects as those described in this article, the density of neocortical NPs was significantly higher in subjects with a CDR rating of 0.5 relative to subjects in the nondemented (CDR rating, 0.0) group. On the other hand, the density of NPs in the neocortex reached a plateau by the time subjects were classified as moderately demented (CDR rating, 2.0). These results, viewed in light of the current findings, suggest that increasing NP densities may be good markers of increasing dementia severity in early phases of AD, while increasing densities of NFTs may represent good markers of dementia severity during the late phases of AD. Accepted for publication September 3, This study was supported by grant P01-AG02219 from the National Institute on Aging, Bethesda, Md. We thank Nicolaos Robakis, PhD, Mount Sinai School of Medicine, New York, NY, for the anti β-amyloid, and Andre Delacourte, PhD, Unite INSERM, Lille, France, for the anti-τ. We also thank James Schmeilder, PhD, Tricia Shreve, Maria Paredes, Anne Peterson, Waseem Ahmed, MD, and Gregory Austin for their help with medical chart reviews, informant interviews, statistical analyses, autopsies, and specimen preparation. Corresponding author: Vahram Haroutunian, PhD, Psychiatry Research, Room 3-F02, Bronx Veteran Affairs Medical Center, 130 W Kingsbridge Rd, Bronx, NY ( vh@doc.mssm.edu). REFERENCES 1. Rogers J, Morrison JH. Quantitative morphology and regional and laminar distribution of senile plaques in Alzheimer s disease. J Neurosci. 1985;5: Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci. 1970;11: Ball M. Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. Acta Neuropathol (Berl). 1977; 37: Khachaturian ZS. Diagnosis of Alzheimer s disease. Arch Neurol. 1985;42: Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer s Disease (CERAD), II: standardization of the neuropathologic assessment of Alzheimer s disease. Neurology. 1991;41: Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82: Braak H, Braak E. Evolution of the neuropathology of Alzheimer s disease. Acta Neurol Scand Suppl. 1996;165: Braak H, Braak E, Bohl J, Reintjes R. Age, neurofibrillary changes, a betaamyloid and the onset of Alzheimer s disease. Neurosci Lett. 1996;210: Hyman BT. The neuropathological diagnosis of Alzheimer s disease: clinicalpathological studies. Neurobiol Aging. 1997;18(suppl 4):S27-S The National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer s Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer s disease. Neurobiol Aging. 1997(suppl 4);18:S1-S Ohm TG, Muller H, Braak H, Bohl J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer s disease related neurofibrillary changes. Neuroscience. 1995;64: Bondareff W, Harrington C, Wischik CM, Hauser DL, Roth M. Immunohistochemical staging of neurofibrillary degeneration in Alzheimer s disease. J Neuropathol Exp Neurol. 1994;53: Ball MJ, Murdoch GH. Neuropathological criteria for the diagnosis of Alzheimer s disease: are we really ready yet? Neurobiol Aging. 1997;18(suppl 4):S4- S Xuereb JH, Gertz HJ, Huppert F, Brayne C, Wischik CM. The application of Braak s staging model of Alzheimer-type pathology to neuropathological diagnosis of dementia. Neuropathol Appl Neurobiol. 1995;21: Price JL. Diagnostic criteria for Alzheimer s disease. Neurobiol Aging. 1997;18 (suppl 4):S67-S Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer s disease. Neurobiol Aging. 1997;18(suppl 4):S85-S Mann DMA. A commentary on the diagnostic criteria for the neuropathological assessment of Alzheimer s disease. Neurobiol Aging. 1997;18(suppl 4):S51- S Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer s disease. Neurobiol Aging. 1991;12: Neary D, Snowden JS, Mann DM, et al. Alzheimer s disease: a correlative study. J Neurol Neurosurg Psychiatry. 1986;49: Wilcock GK, Esiri MM. Plaques, tangles and dementia: a quantitative study. J Neurol Sci. 1982;56: Bouras C, Hof PR, Morrison JH. Neurofibrillary tangle densities in the hippocampal formation in a non-demented population define subgroups of patients with differential early pathologic changes. Neurosci Lett. 1993;153: Giannakopoulos P, Hof PR, Giannakopoulos A, Herrmann FR, Michel J, Bouras C. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of very old patients. Arch Neurol. 1995;52: Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J Neurol Sci. 1968;7: Dickson DW. Neuropathological diagnosis of Alzheimer s disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging. 1997;18(suppl 4):S21-S Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer s disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55: Haroutunian V, Perl DP, Purohit DP, et al. Regional distribution of neuritic plaques in nondemented elderly and cases of very mild Alzheimer disease. Arch Neurol. 1998;55: Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Arch Neurol. 1993;43: Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140: Heyman A, Wilkinson WE, Hurwitz BJ, et al. Early-onset Alzheimer s disease: clinical predictors of institutionalization and death. Neurology. 1987;37: Folstein M, Folstein S, McHugh P. Mini-Mental State : a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer s disease. Am J Psychiatry. 1984;141: Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer s disease. Neurology. 1988;38: Gomez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer s disease. J Neurosci. 1996;16: Braak H, Braak E. Staging of Alzheimer s disease: related neurofibrillary changes. Neurobiol Aging. 1995;16: Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30: Bierer L, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer s disease: relative importance of the cholinergic deficits. J Neurochem. 1995;64:

ORIGINAL CONTRIBUTION. Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects With Very Mild Alzheimer Disease

ORIGINAL CONTRIBUTION. Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects With Very Mild Alzheimer Disease ORIGINAL CONTRIBUTION Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects With Very Mild Alzheimer Disease Vahram Haroutunian, PhD; Daniel P. Perl, MD; Dushyant P. Purohit,

More information

ACENTRAL TENET OF ALZHEIMER

ACENTRAL TENET OF ALZHEIMER CLINICAL INVESTIGATION Cholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease Kenneth L. Davis, MD Richard C. Mohs, PhD Deborah Marin, MD Dushyant P. Purohit, MD Daniel P. Perl,

More information

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration

More information

Preclinical AD revisited

Preclinical AD revisited 32. Kaskie B, Storandt M. Visuospatial deficit in dementia of the Alzheimer type. Arch Neurol 1995;52:422 425. 33. Wilson B, Cockburn J, Halligan P. Behavioural inattention test [in Japanese]. Tokyo: Shinkoh

More information

ORIGINAL ARTICLE. Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease

ORIGINAL ARTICLE. Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease ORIGINAL ARTICLE Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease Pietro Tiraboschi, MD; Larry A. Hansen, MD; Michael Alford, BA; Annette Merdes, MD;

More information

INTERRELATED biological factors in addition to age can. Type 2 Diabetes Is Negatively Associated With Alzheimer s Disease Neuropathology

INTERRELATED biological factors in addition to age can. Type 2 Diabetes Is Negatively Associated With Alzheimer s Disease Neuropathology Journal of Gerontology: MEDICAL SCIENCES 2005, Vol. 60A, No. 4, 471 475 Copyright 2005 by The Gerontological Society of America Type 2 Diabetes Is Negatively Associated With Alzheimer s Disease Neuropathology

More information

NIH Public Access Author Manuscript Arch Neurol. Author manuscript; available in PMC 2012 June 19.

NIH Public Access Author Manuscript Arch Neurol. Author manuscript; available in PMC 2012 June 19. NIH Public Access Author Manuscript Published in final edited form as: Arch Neurol. 2007 August ; 64(8): 1193 1196. doi:10.1001/archneur.64.8.1193. Dissociation of Neuropathologic Findings and Cognition:

More information

Age, Neuropathology, and Dementia

Age, Neuropathology, and Dementia The new england journal of medicine original article Age, Neuropathology, and Dementia George M. Savva, Ph.D., Stephen B. Wharton, F.R.C.Path., Paul G. Ince, M.D., Gillian Forster, B.Sc., Fiona E. Matthews,

More information

Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases

Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer

More information

doi: /brain/awq141 Brain 2010: 133; Age, Alzheimer s disease and dementia in the Baltimore Longitudinal Study of Ageing

doi: /brain/awq141 Brain 2010: 133; Age, Alzheimer s disease and dementia in the Baltimore Longitudinal Study of Ageing doi:10.1093/brain/awq141 Brain 2010: 133; 2225 2231 2225 BRAIN A JOURNAL OF NEUROLOGY Age, Alzheimer s disease and dementia in the Baltimore Longitudinal Study of Ageing David Dolan, 1 Juan Troncoso, 2

More information

Estimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale

Estimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale Estimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale Seong Hye Choi, M.D.*, Duk L. Na, M.D., Byung Hwa Lee, M.A., Dong-Seog Hahm, M.D., Jee Hyang Jeong, M.D.,

More information

ORIGINAL CONTRIBUTION. The Relative Frequency of Dementia of Unknown Etiology Increases With Age and Is Nearly 50% in Nonagenarians

ORIGINAL CONTRIBUTION. The Relative Frequency of Dementia of Unknown Etiology Increases With Age and Is Nearly 50% in Nonagenarians ORIGINAL CONTRIBUTION The Relative Frequency of Dementia of Unknown Etiology Increases With Age and Is Nearly 50% in Nonagenarians Howard A. Crystal, MD; Dennis Dickson, MD; Peter Davies, PhD; David Masur,

More information

ORIGINAL CONTRIBUTION. Cerebrospinal Fluid -Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic

ORIGINAL CONTRIBUTION. Cerebrospinal Fluid -Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic ORIGINAL CONTRIBUTION Cerebrospinal Fluid -Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain Tero Tapiola, MD, PhD; Irina Alafuzoff, MD, PhD; Sanna-Kaisa Herukka,

More information

Synaptic changes in dementia: links to cognition and behaviour

Synaptic changes in dementia: links to cognition and behaviour Synaptic changes in dementia: links to cognition and behaviour Paul T Francis, PhD Professor of Neurochemistry Director, Brains for Dementia Research Agenda Discuss synaptic changes in various dementias

More information

The Spectrum of Age-Associated Astroglial Tauopathies. Dennis W. Dickson MD Department of Neuroscience Mayo Clinic, Jacksonville, FL

The Spectrum of Age-Associated Astroglial Tauopathies. Dennis W. Dickson MD Department of Neuroscience Mayo Clinic, Jacksonville, FL The Spectrum of Age-Associated Astroglial Tauopathies Dennis W. Dickson MD Mayo Clinic, Jacksonville, FL Thorn-shaped astrocytes TSA were first reported by Ikeda (1995), as tau-positive astrocytes in various

More information

Southwest Brain Bank

Southwest Brain Bank Southwest Brain Bank Texas Tech University Health Sciences Center Paul L. Foster School of Medicine Department of Psychiatry Peter Thompson, M.D., M.S. Director Angelica Forero, M.A. Senior Research Scientist

More information

UDS Progress Report. -Standardization and Training Meeting 11/18/05, Chicago. -Data Managers Meeting 1/20/06, Chicago

UDS Progress Report. -Standardization and Training Meeting 11/18/05, Chicago. -Data Managers Meeting 1/20/06, Chicago UDS Progress Report -Standardization and Training Meeting 11/18/05, Chicago -Data Managers Meeting 1/20/06, Chicago -Training material available: Gold standard UDS informant and participant interviews

More information

NACC Vascular Consortium. NACC Vascular Consortium. NACC Vascular Consortium

NACC Vascular Consortium. NACC Vascular Consortium. NACC Vascular Consortium NACC Vascular Consortium NACC Vascular Consortium Participating centers: Oregon Health and Science University ADC Rush University ADC Mount Sinai School of Medicine ADC Boston University ADC In consultation

More information

Lewy body disease (LBD) is the second most common

Lewy body disease (LBD) is the second most common REGULAR ARTICLES Lewy Body Disease: Can We Diagnose It? Michelle Papka, Ph.D. Ana Rubio, M.D., Ph.D. Randolph B. Schiffer, M.D. Christopher Cox, Ph.D. The authors assessed the accuracy of published clinical

More information

NACC Neuropathology (NP) Diagnosis Coding Guidebook

NACC Neuropathology (NP) Diagnosis Coding Guidebook Department of Epidemiology, School of Public Health and Community Medicine, University of Washington 4311 11 th Avenue NE #300 Seattle, WA 98105 phone: (206) 543-8637; fax: (206) 616-5927 e-mail: naccmail@u.washington.edu

More information

V ascular dementia is recognised as one of the most common

V ascular dementia is recognised as one of the most common PAPER Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss J J Kril, S Patel, A J Harding, G M Halliday... See end of article for authors affiliations...

More information

Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease

Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease John C. Morris, MD Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology Disclosure Statement

More information

ORIGINAL CONTRIBUTION. Diagnostic Validity of the Dementia Questionnaire for Alzheimer Disease

ORIGINAL CONTRIBUTION. Diagnostic Validity of the Dementia Questionnaire for Alzheimer Disease ORIGINAL CONTRIBUTION Diagnostic Validity of the Dementia Questionnaire for Alzheimer Disease Ronald J. Ellis, MD, PhD; Kaining Jan, MD; Claudia Kawas, MD; William C. Koller, MD; Kelly E. Lyons, PhD; Dilip

More information

Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study

Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study Neurobiology of Aging 26 (2005) 341 347 Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study Kathryn P. Riley a,b,, David A. Snowdon b,c, Mark F.

More information

Alzheimer disease (AD) is a devastating neurodegenerative

Alzheimer disease (AD) is a devastating neurodegenerative ORIGINAL ARTICLE Rates of Depression in Individuals With Pathologic But Not Clinical Alzheimer Disease are Lower Than Those in Individuals Without the Disease: Findings From the Baltimore Longitudinal

More information

Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical

Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical 161Journal of Neurology, Neurosurgery, and Psychiatry 1997;62:16-21 Alzheimer's Treatment and Research Center, Department of Neurology, Ramsey Clinic/Health- Partners, University of Minnesota, St Paul,

More information

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal

More information

Dementia and Healthy Ageing : is the pathology any different?

Dementia and Healthy Ageing : is the pathology any different? Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association

More information

A lzheimer s disease has many neuropsychiatric manifestations

A lzheimer s disease has many neuropsychiatric manifestations 1396 PAPER Right prosubiculum amyloid plaque density correlates with anosognosia in Alzheimer s disease G A Marshall, D I Kaufer, O L Lopez, G R Rao, R L Hamilton, S T DeKosky... See end of article for

More information

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Publishing Pty Ltd593274279Original ArticleDementia and mild AlzheimersJ. Shimabukuro et al. Psychiatry and

More information

Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy- Confirmed Dementia With Lewy Bodies

Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy- Confirmed Dementia With Lewy Bodies Article Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy- Confirmed Dementia With Lewy Bodies Clive G. Ballard, M.R.C.Psych., M.D. Robin Jacoby, F.R.C.Psych.,

More information

Abnormal Facehand Testing is Associated with Anosognosia in Patients with Neuropathologicallyconfirmed Alzheimer s Disease

Abnormal Facehand Testing is Associated with Anosognosia in Patients with Neuropathologicallyconfirmed Alzheimer s Disease Abnormal Facehand Testing is Associated with Anosognosia in Patients with Neuropathologicallyconfirmed Alzheimer s Disease Item Type Thesis Authors Derksen, Brenna Publisher The University of Arizona.

More information

THE RELATIONSHIP OF PLAQUES, TANGLES, AND LEWY TYPE ALPHA SYNUCLEINOPATHY TO VISUAL HALLUCINATIONS IN PARKINSON S DISEASE AND ALZHEIMER S DISEASE

THE RELATIONSHIP OF PLAQUES, TANGLES, AND LEWY TYPE ALPHA SYNUCLEINOPATHY TO VISUAL HALLUCINATIONS IN PARKINSON S DISEASE AND ALZHEIMER S DISEASE THE RELATIONSHIP OF PLAQUES, TANGLES, AND LEWY TYPE ALPHA SYNUCLEINOPATHY TO VISUAL HALLUCINATIONS IN PARKINSON S DISEASE AND ALZHEIMER S DISEASE A Thesis submitted to the University of Arizona College

More information

Cognition in Schizophrenia: Natural History, Assessment, and Clinical Importance Richard C. Mohs, Ph.D.

Cognition in Schizophrenia: Natural History, Assessment, and Clinical Importance Richard C. Mohs, Ph.D. Cognition in Schizophrenia: Natural History, Assessment, and Clinical Importance Richard C. Mohs, Ph.D. Retrospective studies have demonstrated that schizophrenic patients often have poor premorbid cognitive

More information

ORIGINAL CONTRIBUTION. Apolipoprotein E 4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies,

ORIGINAL CONTRIBUTION. Apolipoprotein E 4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies, ORIGINAL CONTRIBUTION Apolipoprotein E 4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies, and Frontotemporal Degeneration Keith A. Josephs, MST, MD; Yoshio Tsuboi,

More information

Treatment of AD with Stabilized Oral NADH: Preliminary Findings

Treatment of AD with Stabilized Oral NADH: Preliminary Findings MS # 200 000 128 Treatment of AD with Stabilized Oral NADH: Preliminary Findings G.G. Kay, PhD, V. N. Starbuck, PhD and S. L. Cohan, MD, PhD Department of Neurology, Georgetown University School of Medicine

More information

ORIGINAL ARTICLE. Increased Hippocampal Plaques and Tangles in Patients With Alzheimer Disease With a Lifetime History of Major Depression

ORIGINAL ARTICLE. Increased Hippocampal Plaques and Tangles in Patients With Alzheimer Disease With a Lifetime History of Major Depression ORIGINAL ARTICLE Increased Hippocampal Plaques and Tangles in Patients With Alzheimer Disease With a Lifetime History of Major Depression Michael A. Rapp, MD, PhD; Michal Schnaider-Beeri, PhD; Hillel T.

More information

Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology

Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology M.S. Beeri, PhD J. Schmeidler, PhD J.M. Silverman, PhD S. Gandy, MD M. Wysocki, BA C.M. Hannigan,

More information

Validity of Family History for the Diagnosis of Dementia Among Siblings of Patients With Late-onset Alzheimer s Disease

Validity of Family History for the Diagnosis of Dementia Among Siblings of Patients With Late-onset Alzheimer s Disease Genetic Epidemiology 15:215 223 (1998) Validity of Family History for the Diagnosis of Dementia Among Siblings of Patients With Late-onset Alzheimer s Disease G. Devi, 1,3 * K. Marder, 1,3 P.W. Schofield,

More information

Brain Bank of the Brazilian Aging Brain Study Group a Collection Focused in Human Control Cases

Brain Bank of the Brazilian Aging Brain Study Group a Collection Focused in Human Control Cases Brain Bank of the Brazilian Aging Brain Study Group a Collection Focused in Human Control Cases Lea Tenenholz Grinberg, M.D, Ph.D Associate Professor of Pathology University of the City of São Paulo Medical

More information

NEUROPSYCHOMETRIC TESTS

NEUROPSYCHOMETRIC TESTS NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract

More information

Lewy Body-Related -Synucleinopathy in Aging

Lewy Body-Related -Synucleinopathy in Aging Journal of Neuropathology and Experimental Neurology Vol. 6, No. 7 Copyright 4 by the American Association of Neuropathologists July, 4 pp. 74 749 Lewy Body-Related -Synucleinopathy in Aging YUKO SAITO,

More information

ALLEN Human Brain Atlas

ALLEN Human Brain Atlas TECHNICAL WHITE PAPER: CASE QUALIFICATION AND DONOR PROFILES The case review process described here was employed for three components of the ALLEN Human Brain Atlas: (1) the Survey; (2) the Neurotransmitter

More information

Baseline Characteristics of Patients Attending the Memory Clinic Serving the South Shore of Boston

Baseline Characteristics of Patients Attending the   Memory Clinic Serving the South Shore of Boston Article ID: ISSN 2046-1690 Baseline Characteristics of Patients Attending the www.thealzcenter.org Memory Clinic Serving the South Shore of Boston Corresponding Author: Dr. Anil K Nair, Chief of Neurology,

More information

Original Article Perivascular Neuritic Dystrophy Associated with Cerebral Amyloid Angiopathy in Alzheimer s Disease

Original Article Perivascular Neuritic Dystrophy Associated with Cerebral Amyloid Angiopathy in Alzheimer s Disease www.ijcep.com/ijcep711002 Original Article Perivascular Neuritic Dystrophy Associated with Cerebral Amyloid Angiopathy in Alzheimer s Disease Kenichi Oshima, Hirotake Uchikado and Dennis W. Dickson Department

More information

ADNI and DIAN Neuropathology Core

ADNI and DIAN Neuropathology Core NI and DIAN Neuropathology Core Update October 14, 2016 Nigel Cairns, PhD, FRCPath Knight RC Neuropathology Core Leader NI Participants Autopsied per Funding Period Autopsy rates for NI1, NI GO, and NI2

More information

Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16

Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16 The impact of FDG PET in degenerative dementia diagnosis Jung Lung, Hsu MD, Ph.D (Utrecht) Section of dementia and cognitive impairment Department of Neurology Chang Gung Memorial Hospital, Linkou, Taipei

More information

ORIGINAL CONTRIBUTION. Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia

ORIGINAL CONTRIBUTION. Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia ORIGINAL CONTRIBUTION Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia Gregory A. Jicha, MD, PhD; Joseph E. Parisi, MD; Dennis W. Dickson, MD; Kris Johnson,

More information

ORIGINAL CONTRIBUTION. Diagnostic Accuracy of Dementia With Lewy Bodies. to be the second

ORIGINAL CONTRIBUTION. Diagnostic Accuracy of Dementia With Lewy Bodies. to be the second ORIGINAL CONTRIBUTION Diagnostic Accuracy of Dementia With Lewy Bodies Ursula Hohl, MD; Pietro Tiraboschi, MD; Lawrence A. Hansen, MD; Leon J. Thal, MD; Jody Corey-Bloom, MD, PhD Background: Diagnostic

More information

CASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories?

CASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories? CASE 49 A 43-year-old woman is brought to her primary care physician by her family because of concerns about her forgetfulness. The patient has a history of Down syndrome but no other medical problems.

More information

Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment (MCI) October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine

More information

Postmortem Studies in Schizophrenia

Postmortem Studies in Schizophrenia Postmortem Studies in Schizophrenia by Peter Powchik, Michael Davidson, Vahram Haroutunian, Stephen M. Qabriel, Dushyant P. Purohit, Daniel P. Perl, Philip D. Harvey, and Kenneth L. Davis Abstract The

More information

FDG-PET e parkinsonismi

FDG-PET e parkinsonismi Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism

More information

Autopsy Committee Sample Autopsy Case. Alzheimer Disease. Authors Ashley Thorburn, MD. Joseph E. Parisi, MD Autopsy Committee

Autopsy Committee Sample Autopsy Case. Alzheimer Disease. Authors Ashley Thorburn, MD. Joseph E. Parisi, MD Autopsy Committee Autopsy Committee Sample Autopsy Case Alzheimer Disease Authors Ashley Thorburn, MD Joseph E. Parisi, MD Autopsy Committee Clinical Summary: A 75-year-old man presented to his primary care physician with

More information

25 th Annual Southern California Alzheimer s Disease Research Conference

25 th Annual Southern California Alzheimer s Disease Research Conference 25 th Annual Southern California Alzheimer s Disease Research Conference New Guidelines and Importance of Brain Donation Thomas J. Montine, MD, PhD Alvord Professor & Chair Department of Pathology University

More information

The most common type of dementia, Alzheimer s disease

The most common type of dementia, Alzheimer s disease -Amyloid Load Is Not Influenced by the Severity of Cardiovascular Disease in Aged and Demented Patients Alafuzoff Irina, MD, PhD; Helisalmi Seppo, PhD; Mannermaa Arto, PhD; Riekkinen Paavo, Sr, MD, PhD;

More information

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative ORIGINAL RESEARCH E. Matsusue S. Sugihara S. Fujii T. Kinoshita T. Nakano E. Ohama T. Ogawa Cerebral Cortical and White Matter Lesions in Amyotrophic Lateral Sclerosis with Dementia: Correlation with MR

More information

Brain dissection protocol for amyotrophic lateral sclerosis/motor neurone disease

Brain dissection protocol for amyotrophic lateral sclerosis/motor neurone disease Brain dissection protocol for amyotrophic lateral sclerosis/motor neurone disease Prepared by Approved by Approved by Revised by Name Signature Date Sampling and biomarker OPtimization and Harmonization

More information

ORIGINAL CONTRIBUTION. An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease

ORIGINAL CONTRIBUTION. An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease ORIGINAL CONTRIBUTION An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease Yaakov Stern, PhD; Diane Jacobs, PhD; James Goldman, MD; Estrella Gomez-Tortosa, PhD; Bradley

More information

NEUROPATHOLOGY BRAIN CUTTING MANUAL LAST UPDATED ON 6/22/2015

NEUROPATHOLOGY BRAIN CUTTING MANUAL LAST UPDATED ON 6/22/2015 NEUROPATHOLOGY BRAIN CUTTING MANUAL LAST UPDATED ON 6/22/2015 Neuropathology Faculty involved in Brain Cutting: Dr. Sandra Camelo-Piragua Dr. Andrew Lieberman (Chief of the Division) Dr. Kathryn A. McFadden

More information

ORIGINAL CONTRIBUTION. Deposition of -Amyloid Subtypes 40 and 42 Differentiates Dementia With Lewy Bodies From Alzheimer Disease

ORIGINAL CONTRIBUTION. Deposition of -Amyloid Subtypes 40 and 42 Differentiates Dementia With Lewy Bodies From Alzheimer Disease ORIGINAL CONTRIBUTION Deposition of -Amyloid Subtypes 40 and 42 Differentiates Dementia With Lewy Bodies From Alzheimer Disease Carol F. Lippa, MD; Kazuharu Ozawa, PhD; David M. A. Mann, PhD; Kazuhiro

More information

The importance of cognitive ageing for understanding dementia

The importance of cognitive ageing for understanding dementia The importance of cognitive ageing for understanding dementia Archana Singh-Manoux, PhD 1,2,3 Mika Kivimäki, PhD 2 * Corresponding author & address: 1 Centre for Research in Epidemiology & Population Health,

More information

Follow this and additional works at:

Follow this and additional works at: Wayne State University DigitalCommons@WayneState Wayne State University Theses 1-1-2011 Neuropathological diagnosis of alzheimer's disease: the relationship between postmortem assessment, cognitive function

More information

Neuropathology of old-age dementia

Neuropathology of old-age dementia Australian Association of Gerontology Adelaide, September 22 2015 Neuropathology of old-age dementia University of Cambridge, Institute of Public Health Suvi R. K. Hokkanen, MD MPH srkh2@medschl.cam.ac.uk

More information

Imaging of Alzheimer s Disease: State of the Art

Imaging of Alzheimer s Disease: State of the Art July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression

More information

ORIGINAL CONTRIBUTION. Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias

ORIGINAL CONTRIBUTION. Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias ORIGINAL CONTRIBUTION Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias Rajka M. Liscic, MD, PhD; Martha Storandt, PhD; Nigel J. Cairns, PhD; John C. Morris, MD Background:

More information

MRI of Pathological Aging Brain

MRI of Pathological Aging Brain MRI of Pathological Aging Brain Yukio Miki Department of Radiology, Osaka City University A variety of pathological changes occur in the brain with aging, and many of these changes can be identified by

More information

Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer s disease

Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer s disease J Neurol Neurosurg Psychiatry 2001;70:483 488 483 Center for Alzheimer Disease and Related Disorders, Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA

More information

C linicians have noted a close association between. Lewy body cortical involvement may not always predict dementia in Parkinson s disease PAPER

C linicians have noted a close association between. Lewy body cortical involvement may not always predict dementia in Parkinson s disease PAPER 852 PAPER Lewy body cortical involvement may not always predict dementia in Parkinson s disease C Colosimo, A J Hughes, L Kilford, A J Lees... See end of article for authors affiliations... Correspondence

More information

Cerebral amyloid angiopathy in dementia and old age

Cerebral amyloid angiopathy in dementia and old age Journal of Neurology, Neurosurgery, and Psychiatry 1986;49:1221-1226 Cerebral amyloid angiopathy in dementia and old age MARGARET M ESIRI, G K WILCOCK* From the Departments of Neuropathology and Geriatric

More information

Dementia with Lewy Bodies. A Distinct Non-Alzheimer Dementia Syndrome?

Dementia with Lewy Bodies. A Distinct Non-Alzheimer Dementia Syndrome? Brain Pathology 8: 299-324(1998) Dementia with Lewy Bodies. A Distinct Non-Alzheimer Dementia Syndrome? Paul G. Ince 1, 2, Elaine K. Perry 1, Chris. M. Morris 1 MRC Neurochemical Pathology Unit 1, University

More information

212 Index C-SB-13,

212 Index C-SB-13, Index A Acetylcholinesterase inhibitor, treatment, 15 Age-associated memory impairment (AAMI), 5 Alzheimer s disease (AD), 40, 95 96 apolipoprotein E genotype and risk for, 58 cellular neurodegeneration

More information

Parkinson e decadimento cognitivo. Stelvio Sestini

Parkinson e decadimento cognitivo. Stelvio Sestini Parkinson e decadimento cognitivo Stelvio Sestini Patients with PD can develop a spectrum of cognitive symptoms Heterogeneity of cognitive deficits The cognitive symptoms can evolve to dementia (Mov Disorder

More information

ANIMAL MODELS OF ALZHEIMER'S DISEASE: ARE THEY VALID AND USEFUL?

ANIMAL MODELS OF ALZHEIMER'S DISEASE: ARE THEY VALID AND USEFUL? ACTA NEUROBIOL. EXP. 1990, 50: 219-223 Symposium "Recovery from brain damage: behavioral and neurochemical approaches'' 4-7 July, 1989, Warsaw, Poland ANIMAL MODELS OF ALZHEIMER'S DISEASE: ARE THEY VALID

More information

1. Middle frontal gyrus at the level of the genu of the corpus callosum.

1. Middle frontal gyrus at the level of the genu of the corpus callosum. 2008 Clinical Diagnosis: Dementia: (i) Alzheimer s disease (ii) Dementia with Lewy bodies (iii) Normal adult brain BrainNet Europe II Project Co-ordinator: Prof. Dr. Hans Kretzschmar Protocol: Block taking,

More information

NIH Public Access Author Manuscript Arch Neurol. Author manuscript; available in PMC 2013 April 03.

NIH Public Access Author Manuscript Arch Neurol. Author manuscript; available in PMC 2013 April 03. NIH Public Access Author Manuscript Published in final edited form as: Arch Neurol. 2012 October ; 69(10): 1326 1331. doi:10.1001/archneurol.2012.1608. Pathologic Accumulation of α-synuclein and Aβ in

More information

Delirium & Dementia. Nicholas J. Silvestri, MD

Delirium & Dementia. Nicholas J. Silvestri, MD Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts

More information

Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005Y2010

Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005Y2010 J Neuropathol Exp Neurol Copyright Ó 2012 by the American Association of Neuropathologists, Inc. Vol. 71, No. 4 April 2012 pp. 266Y273 ORIGINAL ARTICLE Accuracy of the Clinical Diagnosis of Alzheimer Disease

More information

Resistance to forgetting associated with hippocampus-mediated. reactivation during new learning

Resistance to forgetting associated with hippocampus-mediated. reactivation during new learning Resistance to Forgetting 1 Resistance to forgetting associated with hippocampus-mediated reactivation during new learning Brice A. Kuhl, Arpeet T. Shah, Sarah DuBrow, & Anthony D. Wagner Resistance to

More information

Type 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky

Type 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Type 2 Diabetes and Brain Disease in Older Adults Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Disclosures to Participants Requirements for Successful Completion: For successful completion,

More information

review of existing studies on ASL in dementia Marion Smits, MD PhD

review of existing studies on ASL in dementia Marion Smits, MD PhD review of existing studies on ASL in dementia Marion Smits, MD PhD Associate Professor of Neuroradiology Department of Radiology, Erasmus MC, Rotterdam (NL) Alzheimer Centre South-West Netherlands, Rotterdam

More information

Opinion 18 December 2013

Opinion 18 December 2013 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 AMYVID 800 MBq/ml solution for injection 10 ml vial (CIP: 34009 585 065 4 3) 15 ml vial (CIP: 34009

More information

Lewy body pathology is a frequent co-pathology in familial Alzheimer s disease

Lewy body pathology is a frequent co-pathology in familial Alzheimer s disease Acta Neuropathol (2003) 105 : 484 488 DOI 10.1007/s00401-003-0670-9 REGULAR PAPER Yuri Trembath Carolyn Rosenberg John F. Ervin Donald E. Schmechel Perry Gaskell Margaret Pericak-Vance Jeffery Vance Christine

More information

Validity of clinical diagnosis in dementia: a

Validity of clinical diagnosis in dementia: a Journal ofneurology, Neurosurgery, and Psychiatry 1 985;48: 1085-1090 Validity of clinical diagnosis in dementia: a prospective clinicopathological study PEKKA K MOLSA, LEO PALJARVI,* JUHA 0 RINNE, URPO

More information

Predictors of disease course in patients with probable Alzheimer's disease

Predictors of disease course in patients with probable Alzheimer's disease Article abstract-the presence of extrapyramidal signs or psychosis may indicate greater disability in patients with probable Alzheimer's disease. We evaluated the ability of these signs, noted at a patient's

More information

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there

More information

SUPPLEMENTARY INFORMATION In format provided by Frank et al. (JULY 2010)

SUPPLEMENTARY INFORMATION In format provided by Frank et al. (JULY 2010) Table 1 Imaging bios for Alzheimer s Visual rating High correlation with Multicenter studies have Accuracy for longitudinal hippocampus volume (R 2 been performed, but changes only at chance about 0.9,

More information

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of

More information

NACC Minimum Data Set (MDS) Public Data Element Dictionary

NACC Minimum Data Set (MDS) Public Data Element Dictionary Department of Epidemiology, School of Public Health and Community Medicine, University of Washington 4311 11 th Avenue NE #300 Seattle, WA 98105 phone: (206) 543-8637; fax: (206) 616-5927 e-mail: naccmail@u.washington.edu

More information

A Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong

A Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong A Dynamic Model of Care for Late Onset Cognitive Impairment Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong Outline The pathogenesis of Late life cognitive impairment A framework

More information

COGNITIVE IMPAIRMENT IN PARKINSON S DISEASE

COGNITIVE IMPAIRMENT IN PARKINSON S DISEASE 1 GENERAL INTRODUCTION GENERAL INTRODUCTION PARKINSON S DISEASE Parkinson s disease (PD) is a neurodegenerative movement disorder, named after James Parkinson who described some of its characteristic

More information

Altered proteins in the aging brain

Altered proteins in the aging brain Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1182 Altered proteins in the aging brain ADILA ELOBEID ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2016 ISSN 1651-6206 ISBN

More information

University of Groningen. Visual hallucinations in Parkinson's disease Meppelink, Anne Marthe

University of Groningen. Visual hallucinations in Parkinson's disease Meppelink, Anne Marthe University of Groningen Visual hallucinations in Parkinson's disease Meppelink, Anne Marthe IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from

More information

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language

More information

Microinfarct Pathology, Dementia, and Cognitive Systems

Microinfarct Pathology, Dementia, and Cognitive Systems Microinfarct Pathology, Dementia, and Cognitive Systems Zoe Arvanitakis, MD, MS; Sue E. Leurgans, PhD; Lisa L. Barnes, PhD; David A. Bennett, MD; Julie A. Schneider, MD, MS Background and Purpose Little

More information

ORIGINAL ARTICLE. Increased Neocortical Neurofibrillary Tangle Density in Subjects With Alzheimer Disease and Psychosis

ORIGINAL ARTICLE. Increased Neocortical Neurofibrillary Tangle Density in Subjects With Alzheimer Disease and Psychosis ORIGINAL ARTICLE Increased Neocortical Neurofibrillary Tangle Density in Subjects With Alzheimer Disease and Psychosis Nuri B. Farber, MD; Eugene H. Rubin, MD, PhD; John W. Newcomer, MD; Dorothy A. Kinscherf,

More information

Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre

Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Today Introduction to CT Introduction to MRI Introduction to nuclear medicine Imaging the dementias The Brain ~ 1.5

More information